Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Constellation PharmaceuticalsZogenixMersana TherapeuticsRhythm PharmaceuticalsTrillium Therapeutics
SymbolNASDAQ:CNSTNASDAQ:ZGNXNASDAQ:MRSNNASDAQ:RYTMNASDAQ:TRIL
Price Information
Current Price$22.29$19.00$16.65$19.71$9.98
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.21.71.21.81.7
Analysis Score3.43.43.43.43.4
Community Score2.42.82.72.62.9
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.02.51.7
Earnings & Valuation Score0.00.60.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$45.29$58.25$26.17$50.67$21.83
% Upside from Price Target103.17% upside206.58% upside57.16% upside157.06% upside118.77% upside
Trade Information
Market Cap$1.07 billion$1.06 billion$1.15 billion$989.07 million$1.03 billion
Beta2.81.62.541.572.27
Average Volume464,673845,6161,048,012482,3181,317,084
Sales & Book Value
Annual RevenueN/A$3.65 million$42.12 millionN/A$120,000.00
Price / SalesN/A290.1327.29N/A8,567.91
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$8.23 per share$5.54 per share$1.64 per share$6.40 per share($0.86) per share
Price / BookN/A3.4310.15N/A-11.60
Profitability
Net Income$-85,550,000.00$-419,500,000.00$-28,210,000.00$-140,730,000.00$-41,620,000.00
EPS($3.04)($3.90)($0.65)($3.86)($1.38)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-8,758.48%-8,772.91%N/AN/A
Return on Equity (ROE)-28.88%-53.91%-45.16%-55.21%-70.00%
Return on Assets (ROA)-24.98%-36.49%-37.53%-50.73%-28.84%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.05%N/A0.02%N/AN/A
Current Ratio15.81%4.58%13.05%13.24%22.44%
Quick Ratio15.81%4.58%13.05%13.25%22.44%
Ownership Information
Institutional Ownership PercentageN/A96.57%N/A88.43%67.46%
Insider Ownership Percentage10.60%3.50%5.30%9.49%N/A
Miscellaneous
Employees15421811090N/A
Shares Outstanding47.86 million55.74 million69.04 million50.18 million103.02 million
Next Earnings Date5/5/2021 (Estimated)5/4/2021 (Estimated)5/14/2021 (Estimated)5/3/2021 (Estimated)5/21/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Trillium Therapeutics (NASDAQ:TRIL) Stock Price Down 5.1%Trillium Therapeutics (NASDAQ:TRIL) Stock Price Down 5.1%
americanbankingnews.com - April 17 at 9:08 AM
Benchmark Initiates Coverage on Trillium Therapeutics (NASDAQ:TRIL)Benchmark Initiates Coverage on Trillium Therapeutics (NASDAQ:TRIL)
americanbankingnews.com - April 14 at 9:18 AM
Trillium Therapeutics (NASDAQ:TRIL) Earns Buy Rating from Analysts at BenchmarkTrillium Therapeutics (NASDAQ:TRIL) Earns Buy Rating from Analysts at Benchmark
marketbeat.com - April 14 at 8:05 AM
Trillium Therapeutics (NASDAQ:TRIL)  Shares Down 5.5% Trillium Therapeutics (NASDAQ:TRIL) Shares Down 5.5%
americanbankingnews.com - April 9 at 2:38 PM
These 3 Stocks Will Make You A Fortune If They SucceedThese 3 Stocks Will Make You A Fortune If They Succeed
finance.yahoo.com - April 1 at 8:55 AM
TSX Fades to End March, Q1TSX Fades to End March, Q1
baystreet.ca - March 31 at 5:52 PM
HC Wainwright Reaffirms Buy Rating for Trillium Therapeutics (NASDAQ:TRIL)HC Wainwright Reaffirms Buy Rating for Trillium Therapeutics (NASDAQ:TRIL)
marketbeat.com - March 22 at 7:49 AM
Trillium Therapeutics (NASDAQ:TRIL) Earns Buy Rating from JonestradingTrillium Therapeutics (NASDAQ:TRIL) Earns Buy Rating from Jonestrading
marketbeat.com - March 19 at 12:26 PM
Trillium Flow Technologies™ acquires Red Point Alloys BVTrillium Flow Technologies™ acquires Red Point Alloys BV
benzinga.com - March 10 at 8:48 AM
Warren Buffett: His Advice on Market CrashesWarren Buffett: His Advice on Market Crashes
ca.finance.yahoo.com - March 5 at 7:15 AM
Trillium Therapeutics is Now Oversold (TRIL)Trillium Therapeutics is Now Oversold (TRIL)
nasdaq.com - March 4 at 1:55 PM
Trillium Therapeutics: A Potentially Undervalued CD47 PlayerTrillium Therapeutics: A Potentially Undervalued CD47 Player
seekingalpha.com - January 20 at 5:26 PM
Proactive news headlines including KWESST Micro Systems, Newrange Gold Corp, Trillium Gold ...Proactive news headlines including KWESST Micro Systems, Newrange Gold Corp, Trillium Gold ...
apnews.com - January 19 at 4:21 PM
CA Proactive news snapshot: Codebase Ventures, Nextleaf Solutions, Aftermath Silver, Trillium Gold Mines, XPhyto Therapeutics UPDATE...CA Proactive news snapshot: Codebase Ventures, Nextleaf Solutions, Aftermath Silver, Trillium Gold Mines, XPhyto Therapeutics UPDATE...
proactiveinvestors.com - January 19 at 4:21 PM
TSX:TRIL (Trillium Therapeutics Inc.)TSX:TRIL (Trillium Therapeutics Inc.)
fool.ca - January 7 at 10:56 PM
My Favorite Biotech Stock for 2021My Favorite Biotech Stock for 2021
finance.yahoo.com - January 4 at 1:38 PM
The Worst Mistake Trillium Investors Can Make Right NowThe Worst Mistake Trillium Investors Can Make Right Now
finance.yahoo.com - January 4 at 1:38 PM
Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides ...Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides ...
apnews.com - December 8 at 3:50 PM
How Did Trillium Stock Perform in 2020?How Did Trillium Stock Perform in 2020?
finance.yahoo.com - December 8 at 10:49 AM
Red-Hot Biotechs to Take Center Stage at Blood Disorder MeetingRed-Hot Biotechs to Take Center Stage at Blood Disorder Meeting
bloomberg.com - December 3 at 2:00 PM
Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual MeetingTrillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - November 25 at 7:15 AM
Trillium Therapeutics Inc BuyTrillium Therapeutics Inc Buy
markets.businessinsider.com - November 18 at 11:06 PM
Trillium: 3Q Earnings SnapshotTrillium: 3Q Earnings Snapshot
sfgate.com - November 16 at 8:57 AM
Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors Industry Veteran Brings Deep Executive and Commercial Experience to Trillium BoardTrillium Therapeutics Appoints Paolo Pucci to Its Board of Directors Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board
financialpost.com - November 12 at 4:24 PM
Trillium Therapeutics Inc OutperformTrillium Therapeutics Inc Outperform
markets.businessinsider.com - October 14 at 1:24 PM
Stocks in play: Trillium Therapeutics Inc.Stocks in play: Trillium Therapeutics Inc.
ca.finance.yahoo.com - October 8 at 5:16 PM
Hedge Funds Are Crazy About Trillium Therapeutics Inc. (TRIL)Hedge Funds Are Crazy About Trillium Therapeutics Inc. (TRIL)
sports.yahoo.com - September 29 at 5:26 PM
Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of DirectorsTrillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Directors
finance.yahoo.com - September 18 at 9:01 AM
DateCompanyBrokerageAction
4/7/2021Constellation PharmaceuticalsRoyal Bank of CanadaReiterated Rating
1/25/2021Constellation PharmaceuticalsBMO Capital MarketsUpgrade
9/24/2020Constellation PharmaceuticalsOppenheimerReiterated Rating
9/3/2020Constellation PharmaceuticalsBrookline Capital ManagementInitiated Coverage
8/9/2020Constellation PharmaceuticalsJefferies Financial GroupReiterated Rating
8/6/2020Constellation PharmaceuticalsHC WainwrightReiterated Rating
6/24/2020Constellation PharmaceuticalsJMP SecuritiesInitiated Coverage
3/11/2020Constellation PharmaceuticalsRobert W. BairdLower Price Target
3/11/2020Constellation PharmaceuticalsCowenReiterated Rating
2/13/2020Constellation PharmaceuticalsSunTrust BanksInitiated Coverage
12/14/2020ZogenixNeedham & Company LLCReiterated Rating
12/2/2020ZogenixMizuhoReiterated Rating
8/24/2020ZogenixRaymond JamesInitiated Coverage
8/6/2020ZogenixNorthland SecuritiesReiterated Rating
6/26/2020ZogenixWilliam BlairReiterated Rating
5/5/2020ZogenixPiper SandlerLower Price Target
3/5/2020ZogenixCitigroupInitiated Coverage
2/28/2020ZogenixLADENBURG THALM/SH SHReiterated Rating
2/14/2020ZogenixStifel NicolausReiterated Rating
1/21/2020ZogenixGuggenheimReiterated Rating
12/6/2019ZogenixPiper Jaffray CompaniesReiterated Rating
3/30/2021Mersana TherapeuticsCredit Suisse GroupInitiated Coverage
11/9/2020Mersana TherapeuticsSVB LeerinkBoost Price Target
9/29/2020Mersana TherapeuticsJPMorgan Chase & Co.Initiated Coverage
6/24/2020Mersana TherapeuticsBTIG ResearchBoost Price Target
9/18/2018Mersana TherapeuticsWedbushBoost Price Target
3/9/2021Rhythm PharmaceuticalsMorgan StanleyBoost Price Target
1/27/2021Rhythm PharmaceuticalsCanaccord GenuityBoost Price Target
11/30/2020Rhythm PharmaceuticalsBank of AmericaDowngrade
1/8/2020Rhythm PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
4/14/2021Trillium TherapeuticsBenchmarkInitiated Coverage
3/19/2021Trillium TherapeuticsJonestradingReiterated Rating
12/8/2020Trillium TherapeuticsBloom BurtonDowngrade
11/18/2020Trillium TherapeuticsCraig HallumBoost Price Target
10/12/2020Trillium TherapeuticsEvercore ISIInitiated Coverage
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.